Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23218934 | 0.94 | TSHR (0.40) | TSHRMAPTKDM4EMTNR1BMTNR1A | |
| SCHEMBL29592393 | 0.94 | TSHR (0.40) | TSHRMAPTKDM4EMTNR1BMTNR1A | |
| SCHEMBL29852502 | 0.94 | TSHR (0.40) | TSHRMAPTKDM4EMTNR1BMTNR1A | |
| SCHEMBL29852992 | 0.93 | TSHR (0.41) | TSHRMAPTKDM4EMTNR1BMTNR1A | |
| SCHEMBL23218923 | 0.93 | TSHR (0.41) | TSHRMAPTKDM4EMTNR1BMTNR1A | |
| SCHEMBL23218933 | 0.92 | TSHR (0.39) | TSHRMAPTKDM4EMTNR1BMTNR1A | |
| SCHEMBL29852990 | 0.92 | TSHR (0.39) | TSHRMAPTKDM4EMTNR1BMTNR1A | |
| SCHEMBL23218184 | 0.92 | SLC22A12 (0.42) | TSHRMAPTKDM4EMTNR1BMTNR1A | |
| SCHEMBL29852784 | 0.92 | SLC22A12 (0.42) | TSHRMAPTKDM4EMTNR1BMTNR1A | |
| SCHEMBL23218119 | 0.88 | TSHR (0.47) | TSHRMAPTKDM4EMTNR1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041238-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | TSHR 847/4885MAPT 234/4885KDM4E 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.